Drugs / Adebelimab
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07348042 | Sep 2025 → Mar 2027 expected | — | Xian-Jun Yu | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06859775 | Apr 2025 → Oct 2026 expected | — | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06589778 | Sep 2024 → Apr 2026 overdue | non-small cell lung carcinoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07336979 | Mar 2025 → Mar 2027 expected | mucosal melanoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06429696 | Jul 2024 → Apr 2026 overdue | small cell lung carcinoma | Nanfang Hospital, Southern Medical University | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06771154 Comparator | Apr 2025 → Apr 2029 expected | endometrial cancer | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06895928 Background | Mar 2025 → Dec 2028 expected | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | adebelimab | “Note: The specific PD-L1 inhibitor is selected by the researcher, such as adebelimab 1200mg iv, q3w; or atezolizumab 1200mg iv d1, q3w; or durvalumab 1500mg iv d1, q3w .” NCT06429696 ↗ |
| Known as | SHR-1316 | “Adebelimab (SHR-1316): injection, 600mg(12mL)/ bottle, intravenous drip” NCT06589778 ↗ |
| Route | Intravenous | “adebelimab 1200mg iv, q3w” NCT06429696 ↗ |